MedTrace Logo

Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients

NCT05748977 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-03-01

No results posted yet for this study

Summary

Chronic obstructive pulmonary disease is heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive ,airflow obstruction.

There are network meta analysis to compare the efficacy and safety of short acting bronchodilators Vs long acting agents in treatment of COPD

Conditions

Interventions

DRUG

SABA SAMA ICS Vs LABA LAMA ICs

Short acting agents,long acting agents ,ics

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • nermen M abuelkassem, Lecturer · MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2024-02-20
Completion
2024-03-20

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05748977 on ClinicalTrials.gov